Ebola Research

From Basic Virology to Approved Treatments: A 50-Year Arc

The studies cited above span five decades, and reading them as a body of work rather than as individual papers reveals a research arc that is worth understanding. The 1977 Pattyn paper documenting first isolation from the 1976 Zaire outbreak was foundational virology — at that point, no one knew how the virus caused disease, where it came from, or whether treatment was possible. The 2020 Jacob et al. Nature Reviews Disease Primers paper represents the current state of that accumulated knowledge: a detailed mechanistic account of how Ebola suppresses the interferon response, targets endothelial cells, and causes vascular collapse. The distance between those two papers is a measure of how much was learned — and how much it cost to learn it, in outbreak deaths and healthcare worker infections.

The PALM trial (Mulangu et al., 2019) is the most clinically significant entry on this list. Its design was unusual: it ran inside the 2018–20 DRC outbreak, using a multi-arm randomized controlled design to compare four experimental treatments under active outbreak conditions. The finding that REGN-EB3 (atoltivimab/maftivimab/odesivimab) reduced 28-day mortality from roughly 49% to 33% — and that the benefit was substantially larger for patients treated early — converted a death sentence into a disease with meaningful survival odds for the first time in Ebola's recorded history. Both approved antivirals (Inmazeb and Ebanga) descend directly from this trial's results.

The vaccine studies tell a similar story with higher stakes. The 2017 Henao-Restrepo Lancet paper reporting 100% ring-vaccination efficacy for Ervebo was not conducted in a controlled laboratory — it was conducted during the 2014–16 West Africa epidemic, when the disease had already killed more than 11,000 people. Ring vaccination (vaccinating concentric rings of contacts around confirmed cases) is the same strategy that eradicated smallpox; the Guinea trial was proof it could work for Ebola. The Janssen prime-boost data cited here extends that coverage with a regimen that can be cold-chain stored differently — a practical consideration that matters enormously in remote outbreak settings.

The 2026 DRC outbreak — caused by Bundibugyo virus, an established but far less-studied ebolavirus species — creates an immediate research gap. Ervebo and the Inmazeb and Ebanga antibody treatments were developed and licensed against Zaire ebolavirus, and their efficacy against Bundibugyo virus is not established; the FDA labels for both antibodies say so in those words. WHO's SAGE concluded on August 19, 2026 that Ervebo should be used against Bundibugyo virus only inside a research protocol, and 2,007 health workers had received it under one by September 6 (WHO DON 617). The only registered Bundibugyo-specific vaccine trial is a Phase 1 study of Moderna's mRNA-1469 in 84 Canadian adults, begun July 31, 2026 (NCT07737717). This analysis reflects the state of published evidence as of September 14, 2026 and is provided for informational purposes only.